Hemoglobin, albumin, lymphocyte, and platelet score as a predictor of prognosis in metastatic gastric cancer

Table 3 Analysis of prognostic factors in terms of overall survival

Features	Median (months)	Univariate analysis		Multivariate analysis
		HR (95%CI)	P value	HR (95%CI)	P value
HALP groups
HALP low	7.5	0.59 (0.41-0.85)	0.004	Reference	0.001
HALP high	10.4			0.53 (0.36-0.78)
NLR groups
NLR low	9.1	1.10 (0.78-1.56)	0.582
NLR high	8.0
PLR groups
PLR low	8.6	1.18 (0.83-1.68)	0.350
PLR high	8.4
Age groups
≤ 63	10.2	1.96 (1.37-2.8)	0.000	Reference	0.060
> 63	6.9			1.47 (0.98-2.19)
ECOG PS
0-1	9.1	1.57 (1.04-2.36)	0.030	Reference	0.850
2	6.9			1.04 (0.66-1.64)
Comorbidity
No	10.2	1.67 (1.18-2.36)	0.004	Reference	0.303
Yes	6.2			1.22 (0.84-1.78)
Diferantiation
Well-moderate	8.6	1.10 (0.78-1.53)	0.600
Poorly-Signet ring cell	8.4
Second line CT
No	4.9	0.24 (0.16-0.35)	0.000	Reference	< 0.001
Yes	15.4			0.23 (0.16-0.34)
De novo metastasis
No	9.2	0.94 (0.65-1.37)	0.754
Yes	8.2
Gender
Female	9.1	1.53 (1.03-2.28)	0.035	Reference	0.051
Male	8.2			1.52 (0.99-2.31)
Tumor location
Fundus, cardia	7.5		0.056
Corpus	8.8			-	-
Antrum, pylor	9.2

CI: Confidence interval; CT: Chemotherapy; HALP: Hemoglobin, albumin, lymphocyte and platelet; HR: Hazard ratio; NLR: Neutrophil/lenfocyte ratio; PLR: Platelet/lenfocyte ratio.